Astrazeneca And 3 Other Stocks Have Very High Payout Ratio
Astrazeneca And 3 Other Stocks Have Very High Payout Ratio
(VIANEWS) – Nuveen Arizona Premium Income Municipal Fund (NAZ), WhiteHorse Finance (WHF), Astrazeneca (AZN) are the highest payout ratio stocks on this list.
（VIANEWS）— Nuveen亚利桑那州保费收益市政基金（NAZ）、WhiteHorse Finance（WHF）、阿斯利康（AZN）是该清单上股息率最高的股票。
We have congregated information about stocks with the highest payout ratio up to now. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.
我们已经收集了有关迄今为止派息率最高的股票的信息。派息率本身并不能保证良好的投资，但它可以衡量是否支付股息以及公司选择如何发行股息。
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
在调查潜在投资时，股息支付率是一个很好的统计数据，因此以下是一些派息率超过30％的股票。
1. Nuveen Arizona Premium Income Municipal Fund (NAZ)
1。Nuveen 亚利桑那州保费收入市政基金 (NAZ)
2000% Payout Ratio
2000% 派息率
Nuveen Arizona Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is managed by Nuveen Asset Management, LLC. It invests in the fixed income markets of Arizona. The fund invests in municipal securities and other related investments the income, exempt from regular federal and Arizona income taxes that are rated Baa or BBB or better and having an average maturity of 18.66 years. It employs fundamental analysis with bottom-up stock picking approach to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor's (S&P) Arizona Municipal Bond Index and Standard & Poor's (S&P) National Municipal Bond Index. The fund was formerly known as Nuveen Arizona Premium Income Municipal Fund. Nuveen Arizona Quality Municipal Income Fund was formed on November 19, 1992 and is domiciled in the United States.
Nuveen亚利桑那州优质市政收益基金是由Nuveen Investments, Inc.推出的封闭式固定收益共同基金，该基金由Nuveen资产管理有限责任公司管理。它投资于亚利桑那州的固定收益市场。该基金将收入投资于市政证券和其他相关投资，免征评级为Baa或BBB或更高且平均到期日为18.66年的常规联邦和亚利桑那州所得税。它采用基本面分析和自下而上的选股方法来创建其投资组合。该基金根据标准普尔（S&P）亚利桑那州市政债券指数和标准普尔（S&P）全国市政债券指数衡量其投资组合的表现。该基金前身为Nuveen亚利桑那州保费收入市政基金。Nuveen 亚利桑那州优质市政收益基金成立于1992年11月19日，总部设在美国。
Earnings Per Share
每股收益
As for profitability, Nuveen Arizona Premium Income Municipal Fund has a trailing twelve months EPS of $-0.13.
至于盈利能力，Nuveen Arizona Premium Income 市政基金的每股收益为-0.13美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -14.88%.
在过去的十二个月中，该公司的股本回报率为负-14.88％，用于衡量企业相对于股东权益的盈利能力。
Volume
音量
Today's last reported volume for Nuveen Arizona Premium Income Municipal Fund is 134026 which is 440.34% above its average volume of 24804.
亚利桑那州Nuveen保费收益市政基金今天上次公布的交易量为134026个，比其平均交易量24804高出440.34％。
2. WhiteHorse Finance (WHF)
2。白马金融 (WHF)
213.24% Payout Ratio
213.24% 派息率
WhiteHorse Finance, LLC is a business development company.
WhiteHorse Finance, LLC是一家业务开发公司。
Earnings Per Share
每股收益
As for profitability, WhiteHorse Finance has a trailing twelve months EPS of $0.68.
至于盈利能力，WhiteHorse Finance的每股收益为0.68美元。
PE Ratio
市盈率
WhiteHorse Finance has a trailing twelve months price to earnings ratio of 18.44. Meaning, the purchaser of the share is investing $18.44 for every dollar of annual earnings.
WhiteHorse Finance过去十二个月的市盈率为18.44。这意味着，该股票的购买者每1美元的年收益将投资18.44美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.74%.
在过去十二个月中，该公司的股本回报率为4.74％，用于衡量企业相对于股东权益的盈利能力。
Sales Growth
销售增长
WhiteHorse Finance's sales growth is negative 2.7% for the present quarter and negative 4.2% for the next.
WhiteHorse Finance本季度的销售增长为负2.7％，下一季度的销售增长为负4.2％。
Yearly Top and Bottom Value
年度最高值和最低值
WhiteHorse Finance's stock is valued at $12.54 at 10:23 EST, below its 52-week high of $13.88 and way higher than its 52-week low of $11.13.
美国东部标准时间10点23分，WhiteHorse Finance的股票估值为12.54美元，低于其52周高点13.88美元，远高于其52周低点11.13美元。
Dividend Yield
股息收益率
According to Morningstar, Inc., the next dividend payment is on Dec 18, 2023, the estimated forward annual dividend rate is 1.54 and the estimated forward annual dividend yield is 12.25%.
根据晨星公司的数据，下一次股息将在2023年12月18日支付，预计的远期年股息率为1.54，预计的远期年度股息收益率为12.25％。
3. Astrazeneca (AZN)
3.阿斯利康 (AZN)
76.72% Payout Ratio
76.72% 派息率
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC是一家生物制药公司，专注于处方药的发现、开发、制造和商业化。该公司上市的肿瘤产品包括Calquence、Enhertu、Faslodex、Imfinzi、Iressa、Koselugo、Lumoxiti、Lynparza、Orpathys、Tagrisso和Zoladex；用于肿瘤学的Andexxa/Ondexxya、Atacand HCT、Atacand HCT、Atacand Plus、Brilinta/Brilique、Bydureon/Byn 用于心血管、肾脏和新陈代谢疾病的 Evenzo、Farxiga/Forxiga、Komboglyze/Kombiglyze XR、Lokelma、Onglyza、Qtern、Xigduo/Xigduo 和 Zestril XR，用于心血管、肾脏和新陈代谢疾病；Accolate、Accoleit、Vanticon、Bevespi Aerosphere、Breztri Aerosphere、Breztri Aerosphere、Breztri Aerosphere、Breztri Aerosphere icanyl Respules and Turbuhaler、Dalisp/Daxas、DuaklirGenuair、Fasenra、Pulmicort、Rhinocort、Saphnelo、Symbicort 和 Tezspire 用于呼吸和免疫学；Kanuma、Soliris、Strensiq 和 Ultomiris 用于罕见疾病。其上市的产品还包括治疗呼吸道合胞病毒的Synagis；治疗流感的Fluenz Tetra/FluMist四价药；以及用于covid-19的Vaxzevria和Evusheld。该公司通过在英国、欧洲其他地区、美洲、亚洲、非洲和大洋洲的分销商和当地代表处为初级保健和专科护理医生提供服务。它与Neurimmune AG签订了合作协议，以开发和商业化 NI006；与Personalis, Inc签订了研究合作以评估新的潜在治疗细胞应用；与Cholesgen（上海）有限公司合作推进高胆固醇血症和相关代谢性疾病的研发，并与BioCity Biopharma合作评估一种用于治疗晚期肝细胞癌的单克隆抗体以及与 Cellectis 签订的合作协议。该公司前身为泽尼卡集团有限公司，并于1999年4月更名为阿斯利康集团。阿斯利康公司成立于1992年，总部位于英国剑桥。
Earnings Per Share
每股收益
As for profitability, Astrazeneca has a trailing twelve months EPS of $1.89.
至于盈利能力，阿斯利康的每股收益为1.89美元。
PE Ratio
市盈率
Astrazeneca has a trailing twelve months price to earnings ratio of 35.01. Meaning, the purchaser of the share is investing $35.01 for every dollar of annual earnings.
阿斯利康过去十二个月的市盈率为35.01。这意味着，该股票的购买者为每1美元的年收益投资35.01美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.32%.
该公司的股本回报率为16.32％，用于衡量企业相对于股东权益的盈利能力。
Yearly Top and Bottom Value
年度最高值和最低值
Astrazeneca's stock is valued at $66.17 at 10:23 EST, way under its 52-week high of $76.56 and higher than its 52-week low of $61.73.
美国东部标准时间10点23分，阿斯利康的股票估值为66.17美元，远低于其52周高点76.56美元，高于其52周低点61.73美元。
Earnings Before Interest, Taxes, Depreciation, and Amortization
利息、税项、折旧和摊销前的收益
Astrazeneca's EBITDA is 5.
阿斯利康的息税折旧摊销前利润为5。
Volume
音量
Today's last reported volume for Astrazeneca is 2364060 which is 58.43% below its average volume of 5687530.
阿斯利康今天公布的交易量为2364060，比其平均成交量5687530低58.43％。
Sales Growth
销售增长
Astrazeneca's sales growth is 6.8% for the current quarter and 13.1% for the next.
阿斯利康本季度的销售增长为6.8％，下一季度的销售增长13.1％。
4. Templeton Emerging Markets Fund (EMF)
4。邓普顿新兴市场基金（EMF）
39.36% Payout Ratio
39.36% 派息率
Templeton Emerging Markets Fund is a closed-ended equity mutual fund launched by Franklin Resources Inc. The fund is managed by Templeton Asset Management Ltd. It invests in the public equity markets of emerging market countries across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in value stocks of companies. The fund employs fundamental analysis with a focus on such factors as long-term earnings, asset value, and cash flow potential to create its portfolio. It benchmarks the performance of its portfolio against the MSCI Emerging Markets Index. Templeton Emerging Markets Fund was formed on February 26, 1987 and is domiciled in the United States.
邓普顿新兴市场基金是由富兰克林资源公司发起的封闭式股票共同基金。该基金由邓普顿资产管理有限公司管理。它投资于全球新兴市场国家的公开股票市场。该基金旨在投资在多元化领域运营的公司的股票。它主要投资于公司的价值股。该基金采用基本面分析，重点关注长期收益、资产价值和现金流潜力等因素来创建其投资组合。它以摩根士丹利资本国际新兴市场指数衡量其投资组合的表现。邓普顿新兴市场基金成立于1987年2月26日，总部设在美国。
Earnings Per Share
每股收益
As for profitability, Templeton Emerging Markets Fund has a trailing twelve months EPS of $1.03.
至于盈利能力，邓普顿新兴市场基金的每股收益为1.03美元。
PE Ratio
市盈率
Templeton Emerging Markets Fund has a trailing twelve months price to earnings ratio of 11.15. Meaning, the purchaser of the share is investing $11.15 for every dollar of annual earnings.
邓普顿新兴市场基金过去十二个月的市盈率为11.15。这意味着，该股票的购买者每1美元的年收益将投资11.15美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.44%.
该公司的股本回报率为7.44％，用于衡量企业相对于股东权益的盈利能力。
Dividend Yield
股息收益率
According to Morningstar, Inc., the next dividend payment is on Dec 14, 2023, the estimated forward annual dividend rate is 0.73 and the estimated forward annual dividend yield is 6.33%.
根据晨星公司的数据，下一次股息将在2023年12月14日支付，预计的远期年股息率为0.73，预计的远期年度股息收益率为6.33％。
Yearly Top and Bottom Value
年度最高值和最低值
Templeton Emerging Markets Fund's stock is valued at $11.48 at 10:23 EST, way under its 52-week high of $13.19 and higher than its 52-week low of $10.58.
美国东部标准时间10点23分，邓普顿新兴市场基金的股票估值为11.48美元，远低于其52周高点13.19美元，高于其52周低点10.58美元。
Revenue Growth
收入增长
Year-on-year quarterly revenue growth grew by 56.1%, now sitting on 8.58M for the twelve trailing months.
季度收入同比增长了56.1％，在过去的十二个月中目前为858万英镑。
Moving Average
移动平均线
Templeton Emerging Markets Fund's value is above its 50-day moving average of $11.40 and under its 200-day moving average of $11.61.
邓普顿新兴市场基金的价值高于其50天移动平均线11.40美元，低于其200天移动平均线11.61美元。
1. 1 (1)
1. 1 (1)
1% Payout Ratio
1% 的支付率
1
1
Earnings Per Share
每股收益
As for profitability, 1 has a trailing twelve months EPS of $1.
至于盈利能力，1的每股收益为1美元。
PE Ratio
市盈率
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
1 过去十二个月的市盈率为 1。这意味着，股票的购买者为每1美元的年收益投资1美元。
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.
在过去的十二个月中，该公司的股本回报率为1％，用于衡量企业相对于股东权益的盈利能力。
Growth Estimates Quarters
增长估算季度
The company's growth estimates for the present quarter and the next is 1% and 1%, respectively.
该公司对本季度和下个季度的增长估计分别为1％和1％。
Stock Price Classification
股票价格分类
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1's stock is considered to be overbought (>=80).
根据随机振荡指标（超买和超卖状况的有用指标），1的股票被视为超买（>=80）。
Revenue Growth
收入增长
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
季度收入同比增长了1％，在过去的十二个月中目前为1。
Volume
音量
Today's last reported volume for 1 is 1 which is 1% above its average volume of 1.
今天上次报告的1交易量为1，比其平均交易量1高出1％。